Skip to Content

Balversa (erdafitinib) Disease Interactions

There are 3 disease interactions with Balversa (erdafitinib):


Erdafitinib (applies to Balversa) hyperphosphatemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phosphate Imbalance

Increases in phosphate levels are a pharmacodynamic effect of erdafitinib. Hyperphosphatemia was reported as adverse reaction in 76% of patients after initiating treatment, with 32% requiring phosphate binders during treatment. Caution and monitoring of phosphate levels is advised in all patients, especially in those at risk or hyperphosphatemia. Follow the manufacturer's dose modification guidelines if required.


Erdafitinib (applies to Balversa) ocular disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Retinal Disorder

Erdafitinib can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect. Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography. Caution and close monitoring is advised in patients with retinal disorders. Follow manufacturers dose modification guidelines in patients at risk or with ocular adverse reactions.


Erdafitinib (applies to Balversa) severe hepatic/renal

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

The pharmacokinetics of erdafitinib in patients with severe renal impairment, renal impairment requiring dialysis, moderate or severe hepatic impairment is unknown. Caution is advised if used in these patients.

Balversa (erdafitinib) drug interactions

There are 206 drug interactions with Balversa (erdafitinib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.